DALLAS, Dec. 14, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces a video investment report featuring Cyclacel Pharmaceuticals Inc. (Nasdaq:CYCC). The video report includes technical analysis, commentary, and industry information you need to know to make an educated investment decision.
The report is available at: http://www.beaconequity.com/i/CYCC
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Cyclacel Pharmaceuticals Inc. (Nasdaq:CYCC) is a diversified biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer and in Phase 1 in combination with seliciclib. Seliciclib, a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(R) Cream for radiation dermatitis, Numoisyn(R) Liquid and Numoisyn(R) Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.
Message Board Search for CYCC: http://www.boardcentral.com/boards/CYCC
Here are a few highlights of the CYCC video chart:
* CYCC recently broke out of its current down trending channel * Hit $1.66 resistance Friday on over 19 million shares traded * Resistance moving forward is $1.66 and $1.90 * Key support levels .93 and .75 to .80 levels * RSI over 70 for the first time since April of 09
Watch more by clicking on the video link below
To view the entire video report visit: http://www.beaconequity.com/i/CYCC
See what investors are saying about CYCC stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.